Cleerly ISCHEMIA vs Viz RV/LV

Viz RV/LV emphasizes rapid, mobile-first access with a high-fidelity DICOM viewer and a HIPAA-compliant communication platform, enabling quick alerts and care coordination for acute conditions. Cleerly ISCHEMIA offers a web-based platform with interactive reports and PowerScribe integration, which is beneficial for radiology workflows, but explicitly states it's not for diagnostic review on mobile devices, limiting its on-the-go usability.

Both tools demonstrate significant clinical value in their respective domains, backed by FDA clearance and clinical validation. Cleerly ISCHEMIA offers comprehensive, personalized insights into coronary artery disease, including non-invasive FFR estimation and plaque characterization, with prognostic utility for future MACE events. Viz RV/LV provides rapid, automated risk stratification for acute pulmonary embolism, which has been shown to reduce in-hospital mortality and expedite critical care decisions. Their distinct applications make a direct comparison of 'better' clinical value difficult.

Both companies maintain opaque pricing models, requiring direct contact for details. While Viz.ai's broader platform has demonstrated a clear path to reimbursement through NTAP for some modules, suggesting recognized value for hospitals, specific pricing for Viz RV/LV is not public. Cleerly ISCHEMIA also has a Category I CPT code, facilitating reimbursement, but its pricing also 'varies by provider'. Without transparent pricing, a definitive winner for 'pricing & value' cannot be determined.

Both tools are FDA-cleared, HIPAA compliant, and offer BAA, indicating strong foundational readiness. However, Viz RV/LV, as part of the broader Viz.ai platform, demonstrates superior enterprise readiness through its extensive deployment in nearly 2,000 hospitals, seamless integration with EHR and PACS, and a comprehensive care coordination platform with real-time alerts and communication. This robust ecosystem and proven scalability across numerous health systems give it an edge over Cleerly's web-based platform and PowerScribe integration.

Cleerly ISCHEMIA represents a significant innovation by offering non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans, moving towards a new standard of care for personalized heart disease diagnosis and treatment planning. While Viz RV/LV is innovative in its rapid, AI-powered care coordination and mobile accessibility for acute conditions, its core function of RV/LV ratio measurement is an automation of an existing diagnostic parameter, rather than a fundamentally new diagnostic insight.

Viz.ai offers more comprehensive and readily available support, including 24/7 urgent support with a guaranteed 15-minute response time for critical issues, along with a detailed knowledge base and dedicated customer success teams. Cleerly provides client support during business hours (M-F, 10 am-6 pm ET) with next-business-day response for after-hours needs, which is less immediate for critical healthcare environments.